US Patent

US10596178 — Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide

Formulation · Assigned to Novartis AG · Expires 2035-07-22 · 9y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a tablet formulation of the cancer treatment drug capmatinib hydrochloride.

USPTO Abstract

The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,-2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.

Drugs covered by this patent

capmatinib-hydrochloride (CAPMATINIB HYDROCHLORIDE)

Patent Metadata

Patent number: US10596178
Jurisdiction: US
Classification: Formulation
Expires: 2035-07-22
Drug substance claim: No
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.